Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Solara Active Pharma Sciences Ltd. Share Price
Day's Range
Day's Range
Low
₹563.30
High
₹584.60
Price Summary
| Previous Close | ₹568.40 |
|---|---|
| Day's Range | ₹563.30 - ₹584.60 |
| Open | ₹574.00 |
| 52 Week Range | ₹422.00 - ₹734.40 |
| Volume | 2,41,140 |
| Market Cap | ₹0.00 |
| Previous Close | ₹566.80 |
|---|---|
| Day's Range | ₹563.00 - ₹586.95 |
| Open | ₹575.45 |
| 52 Week Range | ₹422.85 - ₹734.20 |
| Volume | 43,126 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,370.64 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -1.54 |
| P/E Ratio | 3820.42 |
| Book Value(₹) | 2.22 |
| PAT Margin (%) | 0.04 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 6.07 |
| Trade Value ( ₹ in Lacs) | 244.44 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -1.54 |
| P/E Ratio | 3820.42 |
| Book Value(₹) | 2.22 |
| PAT Margin (%) | 0.04 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 6.07 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 12837.6 | 2730.1 |
| Expenses | N/A | N/A |
| PBT | -10.8 | -48.8 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -10.8 | -48.8 |
About Solara Active Pharma Sciences Ltd.
| Founded | 2017 |
|---|---|
| Managing Director | Sandeep Rao |
| NSE Symbol | SOLARA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,26,937.66 | 1,788.10 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,361.19 | 6,735.85 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,384.95 | 4,491.30 | 3,140.10 - 3,140.10 |
| Apollo Hospitals Enterprise Ltd. | 1,22,585.05 | 8,544.90 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,11,264.32 | 1,108.00 | 835.50 - 835.50 |
| Cipla Ltd. | 1,11,220.10 | 1,380.60 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,05,898.64 | 1,275.20 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,490.01 | 2,265.40 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 98,745.27 | 2,399.90 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 97,640.68 | 1,020.55 | 903.00 - 903.00 |
No Records Found
Latest News
Solara Active Pharma Sciences informs about allotment of shares
Solara Active Pharma Sciences has informed that pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) and Regulation 10(c) of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, (‘SEBI SBEB & SE Regulations’), the Board of Directors have approved the allotment of 2,200 Equity Shares of face value Rs 10 each fully paid up against the exercise of vested Options of Solara Employee Stock Option Plan 2018. The equity shares so allotted under the aforesaid Scheme, shall rank with the existing equity shares of the Company in all respects. Consequent to the aforesaid allotment, the paid‐up share capital of the Company will accordingly increase, as details enclosed. In terms of Regulation 10(c) read with Part - E of the SEBI SBEB & SE Regulations, the details of the shares allotted are enclosed as ‘Annexure-A; and the details required as per Master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as ‘Annexure -B’.
The above information is a part of company’s filings submitted to BSE.
Solara Active Pharma Sciences informs about analyst meet
Solara Active Pharma Sciences has informed that the Company has scheduled a conference call with analysts/ investors to discuss Company’s audited financial results for the quarter and financial year ended March 31, 2026 on Friday, May 15, 2026 at 03:00 pm (IST). Analysts / Investors Conference Call details are enclosed. Further, the above information will also be available on the website of the Company: https://solara.co.in/investor-relations/schedule-of-investors-meet-and-investors-presentations.
The above information is a part of company’s filings submitted to BSE.
Solara Active Pharma Sciences informs about outcome of rights issue committee meeting
Solara Active Pharma Sciences has informed that the Meeting of the Rights Issue Committee of the Board of Directors of the Company held today, Tuesday, March 24, 2026 has considered and approved the making of Second & Final call of ₹ 112.50/- per equity shares (₹ 3.00/- towards face value and ₹ 109.50/- towards securities premium) per Rights Share in respect of partly-paid Rights Shares, on Rights basis, pursuant to the Letter of Offer dated May 09, 2024. Rights Issue Committee has fixed Thursday, April 02, 2026, as the Record date for the purpose of determining the holders of partly paid-up Equity Shares to whom the call notice will be dispatched for payment of the call. Details under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been enclosed as Annexure I. The Rights Issue Committee Meeting commenced at 9.30 am and concluded at 9.55 am.
The above information is a part of company’s filings submitted to BSE.
Beryl Drugs informs about disclosure
Concord Biotech informs about updates
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Solara Active Pharma Sciences Ltd. is ₹568.40 as of 2026-06-10.
The market capitalisation of Solara Active Pharma Sciences Ltd. is ₹2,784.20 as of 2026-06-09.
The 1-year return of Solara Active Pharma Sciences Ltd. is -11.60% as of 2026-06-10.
The P/E ratio of Solara Active Pharma Sciences Ltd. is 3820.42 as of 2026-06-10.
The 52-week high and low of Solara Active Pharma Sciences Ltd. are ₹734.40 and ₹422.00, respectively, as of 2026-06-10.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
